Processes for preparing quetiapine and salts thereof
    1.
    发明申请
    Processes for preparing quetiapine and salts thereof 审中-公开
    制备喹硫平及其盐的方法

    公开(公告)号:US20060063927A1

    公开(公告)日:2006-03-23

    申请号:US11229678

    申请日:2005-09-20

    IPC分类号: C07D498/02

    CPC分类号: C07D285/36

    摘要: The present invention provides herein a two-step process for preparing pharmaceutically pure quetiapine and salts thereof by obtaining the starting material 11-chloro-dibenzo-thiazepine followed by reacting the 11-chloro-dibenzo-thiazepine with 1-(2-hydroxyethoxy)ethylpiperazine, or its salt, in the presence of an inorganic or organic base in an organic solvent or in a two-phase solvent system. The present invention provides also a novel, one-pot reaction process for preparing pharmaceutically pure quetiapine and salts thereof. The two processes provided herein can be easily, conveniently and inexpensively scaled-up.

    摘要翻译: 本发明在此提供了制备药学上纯的喹硫平及其盐的两步法,其方法是通过获得原料11-氯 - 二苯并 - 氮杂,然后将11-氯 - 二苯并噻吖庚因与1-(2-羟基乙氧基)乙基哌嗪 ,或其盐,在无机或有机碱存在下在有机溶剂中或在两相溶剂体系中。 本发明还提供了一种用于制备药学上纯的喹硫平及其盐的新型一锅反应方法。 这里提供的两个方法可以容易地,方便地和低成本地放大。

    Novel processes for preparing substantially pure anastrozole
    5.
    发明申请
    Novel processes for preparing substantially pure anastrozole 审中-公开
    用于制备基本上纯的阿那曲唑的新方法

    公开(公告)号:US20060035950A1

    公开(公告)日:2006-02-16

    申请号:US11199226

    申请日:2005-08-09

    IPC分类号: C07D249/08 A61K31/4196

    摘要: The present invention provides novel processes for purifying anastrozole, devoid of using liquid chromatography. The purification processes are via the isolated anastrozole salt forms, either by crystallization or by selective acidic extractions, and optionally in both cases, converting the purified anastrozole salt to anastrozole base. Also provided is an improved process for the synthesis of anastrozole, which is obtained by alkylating the isolated and purified starting material 3,5-bis(2-cyanoprop-2-yl)benzylbromide, the process being devoid of using toxic, hazardous and environmental unfriendly solvents and reagents.

    摘要翻译: 本发明提供了不使用液相色谱法纯化阿那曲唑的新方法。 纯化过程通过分离的阿那曲唑盐形式,通过结晶或通过选择性酸性提取,并且任选地在两种情况下,将纯化的阿那曲唑盐转化成阿那曲唑碱。 还提供了用于合成阿那曲唑的改进方法,其通过将分离和纯化的起始物质3,5-双(2-氰基丙-2-基)苄基溴化物烷基化而获得,该方法没有使用有毒,危险和环境 不友好的溶剂和试剂。

    Highly pure cilostazol and an improved process for obtaining same
    6.
    发明申请
    Highly pure cilostazol and an improved process for obtaining same 失效
    高纯度西洛他唑和改进的获得相同的方法

    公开(公告)号:US20050222202A1

    公开(公告)日:2005-10-06

    申请号:US11080460

    申请日:2005-03-16

    CPC分类号: C07D401/12

    摘要: A novel process for preparing highly pure cilostazol, effected by reacting 6-hydroxy-3,4-dihydroquinolinone and 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in the presence of a hydrated inorganic base, is disclosed. Further disclosed is highly pure cilostazol, and particularly highly pure cilostazol that is substantially free of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl]-3,4-dihydro-1H-quinolin-2-one.

    摘要翻译: 公开了一种通过在水合无机碱存在下使6-羟基-3,4-二氢喹啉酮和5-(4-氯丁基)-1-环己基-1H-四唑反应制备高纯度西洛他唑的新方法。 进一步公开的是高纯度西洛他唑,特别是高纯度西洛他唑,其基本上不含6- [4-(1-环己基-1H-四唑-5-基) - 丁氧基] -1- [4-(1-环己基-1H - 四唑-5-基) - 丁基] -3,4-二氢-1H-喹啉-2-酮。

    Highly pure cilostazol and an improved process for obtaining same
    7.
    发明授权
    Highly pure cilostazol and an improved process for obtaining same 失效
    高纯度西洛他唑和改进的获得相同的方法

    公开(公告)号:US07524960B2

    公开(公告)日:2009-04-28

    申请号:US11080460

    申请日:2005-03-16

    IPC分类号: C07D215/38

    CPC分类号: C07D401/12

    摘要: A novel process for preparing highly pure cilostazol, effected by reacting 6-hydroxy-3,4-dihydroquinolinone and 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole in the presence of a hydrated inorganic base, is disclosed. Further disclosed is highly pure cilostazol, and particularly highly pure cilostazol that is substantially free of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butyl ]-3,4-dihydro-1H-quinolin-2-one.

    摘要翻译: 公开了一种通过在水合无机碱存在下使6-羟基-3,4-二氢喹啉酮和5-(4-氯丁基)-1-环己基-1H-四唑反应制备高纯度西洛他唑的新方法。 进一步公开的是高纯度西洛他唑,特别是高纯度的西洛他唑,其基本上不含6- [4-(1-环己基-1H-四唑-5-基) - 丁氧基] -1- [4-(1-环己基-1H - 四唑-5-基) - 丁基] -3,4-二氢-1H-喹啉-2-酮。

    Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof
    8.
    发明申请
    Processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone and the use in aripiprazole preparation thereof 审中-公开
    制备7-羟基-3,4-二氢-2(1H) - 喹啉酮的方法及其在阿立哌唑制备中的应用

    公开(公告)号:US20060079690A1

    公开(公告)日:2006-04-13

    申请号:US11246278

    申请日:2005-10-11

    IPC分类号: C07D215/36

    CPC分类号: C07D215/227 C07D215/22

    摘要: The present invention provides improved processes for preparing the intermediate 7-hydroxy-3,4-dihydro-2(1H)-quinolinone (7-HQ), which may be used in preparing the drug aripiprazole. Among these processes are included three efficient processes for preparing 7-hydroxy-3,4-dihydro-2(1H)-quinolinone comprising reacting N-(3-methoxyphenyl)-3-chloropropionamide with AlCl3 using novel reaction conditions thus obtaining a substantially pure product, which may be used in the subsequent steps for obtaining aripiprazole without further purification.

    摘要翻译: 本发明提供了制备中间体7-羟基-3,4-二氢-2(1H) - 喹啉酮(7-HQ)的改进方法,其可用于制备药物阿立哌唑。 其中包括制备7-羟基-3,4-二氢-2(1H) - 喹啉酮的三种有效方法,包括使N-(3-甲氧基苯基)-3-氯丙酰胺与AlCl 3 3反应,使用 因此获得基本上纯的产物,其可以用于随后的步骤中用于在不进一步纯化的情况下获得阿立哌唑。

    Imatinib mesylate alpha form and production process therefor
    9.
    发明申请
    Imatinib mesylate alpha form and production process therefor 审中-公开
    甲磺酸伊马替尼α形式及其制备方法

    公开(公告)号:US20060223816A1

    公开(公告)日:2006-10-05

    申请号:US11429731

    申请日:2006-05-08

    IPC分类号: A61K31/506 C07D403/14

    CPC分类号: C07D401/04

    摘要: Provided is a process for preparing crystalline imatinib mesylate in substantially pure α-form, which preferably includes crystallizing imatinib mesylate from an organic solvent containing imatinib and methanesulfonic acid, and seed crystals of imatinib mesylate α-form, wherein the seed crystals are added before imatinib mesylate begins to precipitate from the mixture. Also provided are stable, free-flowing imatinib mesylate crystals in substantially pure α-form, and a pharmaceutical composition containing the stable, free-flowing imatinib mesylate crystals.

    摘要翻译: 本发明提供了一种以基本上纯的α形式制备结晶伊马替尼甲磺酸盐的方法,其优选包括从含有伊马替尼和甲磺酸的有机溶剂中结晶甲磺酸伊马替尼以及甲磺酸伊马替尼α-型的晶种,其中在伊马替尼之前加入晶种 甲磺酸盐从混合物开始沉淀。 还提供了基本上纯α形式的稳定的,自由流动的甲磺酸伊马替尼晶体,以及含有稳定的自由流动的伊马替尼甲磺酸盐晶体的药物组合物。